This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular Dystrophies (FSHD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
aTyr Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT02579239
First received: September 28, 2015
Last updated: May 15, 2017
Last verified: May 2017
  Purpose
The purpose of this study is to assess the safety and biological activity of ATYR1940 in patients with Limb Girdle (LGMD2B) or Facioscapulohumeral Muscular Dystrophy (FSHD).

Condition Intervention Phase
Limb-Girdle Muscular Dystrophies Facioscapulohumeral Muscular Dystrophy Biological: ATYR1940 Biological: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies

Resource links provided by NLM:


Further study details as provided by aTyr Pharma, Inc.:

Primary Outcome Measures:
  • Tolerability Primary Outcome Measure - incidence of treatment-emergent adverse events (AEs) and serious adverse events overal (SAEs) overall and by intensity [ Time Frame: 12 weeks ]
    Incidences of Adverse Events (AEs), including serious and severe AEs

  • Safety Primary Outcome Measure - change from Baseline in safety laboratory test results [ Time Frame: 12 weeks ]
    Change from Baseline in safety laboratory test results (clinical chemistry, hematology, and urinalysis)

  • Safety Primary Outcome Measure - change from Baseline in ECG [ Time Frame: 12 weeks ]
    Change from Baseline in 12-lead ECG findings

  • Safety Primary Outcome Measure - change from Baseline in vital signs measurements and pulmonary evaluations [ Time Frame: 12 week ]
    Change from Baseline in vital signs measurements (blood pressure, pulse, respiratory rate, and body temperature) and pulmonary evaluations (PFTs and pulse oximetry)


Secondary Outcome Measures:
  • Pharmacodynamic Additional Outcome Measure - changes in muscular dystrophy-related inflammatory immune state [ Time Frame: 12 weeks ]
    Effects assessed by changes in muscular dystrophy-related inflammatory immune state in peripheral blood

  • Pharmacodynamic Additional Outcome Measure - changes in serum- and/or plasma-based muscle biomarkers. [ Time Frame: 12 weeks ]
    Serum-based muscle biomarkers


Enrollment: 18
Actual Study Start Date: November 5, 2015
Study Completion Date: October 5, 2016
Primary Completion Date: October 5, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATYR1940
Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
Biological: ATYR1940
Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
Placebo Comparator: Placebo
Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
Biological: Placebo
Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.

Detailed Description:
ATYR1940-C-004 is a Phase1b/2 open-label intrapatient study dose escalation study aiming to evaluate the safety, tolerability, immunogenicity, biological activity of intravenous ATYR1940, administered once weekly for 8 weeks, then twice a weekly for 4 weeks in adult patients with LGMD2B and FSHD. Approximately 8 LGMD2B and 8 FHSD patients will be enrolled.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provided informed consent
  • Investigator's opinion, patient is willing and able to complete all study procedures and comply with the study visit schedule.

Patients with LGMD2B:

  • Established, genetically confirmed diagnosis of LGMD2B.
  • Either the presence of a STIR-positive muscle on lower extremity skeletal muscle MRI, or, if no STIR-positive muscles, meets muscle biomarker criteria.

Patients with FSHD:

  • Established, genetically confirmed diagnosis of FSHD.
  • The presence of a STIR-positive muscle on lower extremity skeletal muscle MRI.

Exclusion Criteria:

  • Currently receiving treatment with an immunomodulatory agent, including targeted biological therapies within the 3 months before baseline; corticosteroids within 3 months before baseline; or high-dose non-steroidal anti-inflammatory agents within 2 weeks before baseline.
  • Currently receiving curcumin or albuterol; use of a product that putatively enhances muscle growth on a chronic basis within 4 weeks before baseline; statin treatment initiation or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
  • Use of an investigational product or device within 30 days before baseline.
  • Evidence of an alternative diagnosis other than LGMD2B or FSHD or a coexisting myopathy or dystrophy, based on prior muscle biopsy or other available investigations.
  • History of severe restrictive or obstructive lung disease or evidence for interstitial lung disease on screening chest radiograph.
  • History of anti-synthetase syndrome, prior Jo-1 Ab-positivity, or a positive or equivocally positive Jo-1 Ab test result during screening.
  • Chronic infection, such as hepatitis B, hepatitis C, or human immunodeficiency virus or a history of tuberculosis.
  • Vaccination within 8 weeks before baseline or vaccination is planned during study participation.
  • Symptomatic cardiomyopathy or severe cardiac arrhythmia that may in the Investigator's opinion, limit the patient's ability to complete the study protocol.
  • Muscle biopsy within 30 days before baseline.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02579239

Locations
United States, California
University of California, Irvine, ALS and Neuromuscular Center
Irvine, California, United States, 92697
United States, Maryland
Kennedy Krieger Institute; The Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21205
United States, Ohio
OSU Wexner Medical Center
Columbus, Ohio, United States, 43210
Denmark
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
France
Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET)
Marseille, France, 13385
Institut de Myologie, Hôpital Pitié-Salpêtrière
Paris, France
Sponsors and Collaborators
aTyr Pharma, Inc.
Investigators
Study Director: Kelly Blackburn aTyr Pharma
  More Information

Responsible Party: aTyr Pharma, Inc.
ClinicalTrials.gov Identifier: NCT02579239     History of Changes
Other Study ID Numbers: ATYR1940-C-004
2015-001910-88 ( EudraCT Number )
Study First Received: September 28, 2015
Last Updated: May 15, 2017

Keywords provided by aTyr Pharma, Inc.:
LGMD2B
FSHD

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
Muscular Dystrophies, Limb-Girdle
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on September 21, 2017